Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-03-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
独立董事关于选举公司董事长及聘任总经理等高级管理人员的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the election and appointment of the company's chairman and senior management personnel. It references compliance with relevant laws and company articles but does not contain financial data or report financial results. It is an announcement related to board and management changes, specifically the election and appointment of key executives. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management appointments, not a full report or announcement of a report publication.
2022-03-25 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the first meeting of the fourth board of directors of Lingkang Pharmaceutical Group Co., Ltd. It details the election and appointment of board members and senior management positions such as chairman, general manager, financial director, and vice general managers. The content focuses on changes in the company's board and senior management personnel. There are no financial statements, audit information, or other report types present. The document is not a full report but an official announcement of board and management changes, fitting the category of Board/Management Information (MANG). The document length is 3529 characters, which is consistent with a detailed announcement rather than a full report.
2022-03-25 Chinese
关于实际控制人股票质押式回购交易延期购回及部分解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the extension of the repurchase period for a stock pledge transaction by the actual controller and partial release of pledged shares. It details the number of shares pledged, the extension of the pledge period, and the impact on the company. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge and financing arrangements, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it concerns stock pledge financing and related updates.
2022-03-18 Chinese
2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2022 First Extraordinary General Meeting (EGM) Meeting Materials" of Lingkang Pharmaceutical Group Co., Ltd. It contains detailed agenda, meeting instructions, and multiple proposals for shareholder approval, including changes to business term, registered capital, amendments to the Articles of Association, and election of board members and supervisors. The content is typical of materials prepared and distributed for a shareholders' meeting, specifically an extraordinary general meeting, rather than a report or announcement of results. It is not a full annual report, audit report, earnings release, or other financial report. It is also not a voting results announcement, but the materials for the meeting itself. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). The document length (8845 characters) and detailed content support this classification with high confidence.
2022-03-18 Chinese
灵康药业集团股份有限公司回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding a share repurchase plan. It includes specifics about the repurchase amount, price, purpose (employee stock ownership plan and equity incentive plan), authorization, risks, and compliance with regulatory requirements. The document is not a financial report or earnings release but a formal disclosure about the company's plan to buy back its own shares. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and related details. The document length and content confirm it is the actual announcement of the repurchase plan, not a brief notice or a report publication announcement.
2022-03-15 Chinese
关于回购事项前十名股东持股信息的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the shareholding information of the top ten shareholders prior to a share repurchase plan. It references a board meeting decision about share repurchase and discloses detailed shareholding percentages of the top shareholders. The content focuses on shareholding changes related to a buyback plan rather than financial results, management changes, or regulatory filings. This fits the definition of a Transaction in Own Shares (POS) filing, which reports the company's buyback or sale of its own shares. The document length is short and it is not a report or a certification, but a specific announcement about shareholding in relation to a repurchase.
2022-03-15 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.